Trump's CBD Reimbursement Program Stalls as Hemp Ban Looms

October 22, 2026

Photo by FitNish Media via Unsplash.

A federal benefit program that promised Medicare and Medicaid patients up to $500 a year toward hemp-derived CBD and THC products is sitting mostly unused, five months after its April 1 launch. The reason isn't mysterious. Congress passed a federal hemp ban in November 2025 that could make most of those same products illegal to sell nationwide by the end of this year, and nobody in the supply chain wants to build out distribution for a product line that might not survive the holidays.

That collision -- a brand-new entitlement program running headlong into a looming prohibition -- has left accountable care organizations, suppliers, and the patients who were supposed to benefit all sitting on their hands. What was pitched as a notable expansion of government-subsidized cannabinoid access has instead become a case study in how fast a federal rollout can stall when the legal ground underneath it is still shifting.

What the Program Was Supposed to Do

President Trump announced the initiative in December 2025 under the name Substance Access Beneficiary Engagement Incentive, a title that was clearly built around an acronym rather than clarity. The Centers for Medicare & Medicaid Services didn't release the operational details providers needed until March 20, 2026 -- just 11 days before the program's April 1 start date. That compressed window would turn out to matter a great deal later.

The basic structure: eligible Medicare and Medicaid beneficiaries could receive up to $500 annually to put toward hemp-derived CBD and THC products, administered through their providers rather than claimed directly. At launch, participation was restricted to providers already enrolled in two existing CMS value-based care models, ACO REACH and the Enhancing Oncology Model. CMS had already mapped out a second expansion phase, folding in the LEAD Model starting January 1, 2027, assuming the first phase proved workable.

CMS Administrator Mehmet Oz, a physician with a long media history of promoting alternative and integrative health approaches, oversaw the rollout personally. Multiple industry sources have pointed to a somewhat unusual origin story for the program: advocacy from a Mar-a-Lago Club member reportedly played a role in getting the concept in front of the administration in the first place. Whatever the origin, the structure CMS ultimately built was narrow by design -- limited providers, a hard dollar cap, and a product category, hemp-derived cannabinoids, that was already drawing fire in Congress even as CMS was finalizing the paperwork to hand patients money to buy it.

A Program Nobody Is Actually Using Yet

Photo by EqualStock via Unsplash.

Nearly half a year in, the numbers tell a plain story. Of the 74 accountable care organizations operating nationwide, only six have been approved by CMS to offer hemp CBD products to beneficiaries, according to a CMS spokesperson. CMS has not said how many of those six are actually moving product to patients versus simply holding approval on paper, which is itself a telling omission from an agency usually eager to tout early participation numbers for a new initiative.

What little real-world activity exists has been concentrated in two states. Patients in New York and Florida began receiving products under the program in May 2026, a full month after launch and well behind the original timeline CMS had sketched out.

The companies positioned to supply this market haven't seen it translate into revenue. Charlotte's Web, one of the most established hemp CBD brands in the country, reported zero revenue attributable to the program in its second-quarter filings. On the company's August earnings call, executives described the rollout as still being in early build-out, a phrase that's doing a lot of work to avoid saying the program hasn't generated a dollar for them yet.

Cornbread Hemp secured an exclusive group purchasing contract with Alliant Purchasing in March 2026, a deal that looked like it could give the Louisville-based company a real foothold with hospital systems and ACOs. Months later, there's no indication that contract has translated into meaningful patient uptake either. The pattern across both companies is the same: approvals and agreements exist on paper, but the actual flow of product to patients has barely started.

The Hemp Ban Casting a Shadow Over Everything

Photo by Tim Mossholder via Unsplash.

The reason suppliers and ACOs are moving so cautiously isn't hard to find. Congress passed a federal hemp ban in November 2025 that would reclassify most non-intoxicating CBD products -- the exact category this CMS program is built around -- as federally illegal. The original effective date was set for November 12, 2026. Industry sources now point to an extended deadline of December 11, following legislative maneuvering that pushed the timeline back, though nothing about the situation feels settled.

Put yourself in the position of an ACO administrator or a hemp supplier right now. Why would you invest in building compliant distribution infrastructure, train staff, set up inventory and reimbursement workflows, for a product that could become federally illegal to sell within weeks of your launch? That's the calculation playing out across the industry, and it explains the gap between the six approved ACOs and whatever smaller number is actually distributing anything.

Industry figures have been blunt about it, describing the reimbursement program as effectively dead on arrival unless Congress acts to guarantee these products can legally remain on shelves past the ban's effective date. Several legislative fixes are in play but none have passed. Sen. Ron Wyden has introduced the Cannabinoid Safety and Regulation Act, aimed at creating a regulatory framework rather than an outright ban. Rep. Jim Baird has proposed a two-year delay on the ban's implementation. Reps. James Comer and Andy Barr have pushed their own efforts to soften or restructure the policy. All of it remains pending, which means the CBD reimbursement program is operating in a kind of legislative limbo, waiting on a Congress that hasn't shown much urgency to resolve the underlying conflict it created.

Why Critics Say This Was Never Going to Work

Photo by CDC via Unsplash.

Smart Approaches to Marijuana CEO Kevin Sabet has been one of the program's loudest critics, calling it taxpayer funded marijuana and arguing that Medicare has no business subsidizing intoxicating hemp-derived products, a category that includes delta-8 and delta-9 THC items sold under the 2018 Farm Bill's hemp definition. That criticism lands differently depending on which products a given ACO is actually distributing, since hemp CBD and hemp-derived THC products occupy very different places on the intoxication spectrum, but Sabet's broader objection is to the federal government underwriting any of it.

Supporters see it differently, framing the program as harm reduction: an option for older patients managing chronic pain who might otherwise turn to opioids, with cannabinoids offered as a lower-risk alternative under medical supervision. That argument has real public health backing in general terms, even if this particular program's execution has given it little chance to prove the case either way.

Execution is really the crux of the problem. Giving providers 11 days between CMS's implementation guidance and a hard launch date left almost no room to build compliant distribution systems, train staff, or line up reliable suppliers, and it shows in how few ACOs have moved past paper approval. Layer onto that the uncertainty around whether the program itself survives administratively, whether the products stay legal past November or December, and CMS's own silence on how it plans to enforce or unwind the program if the ban takes effect as written, and you get a policy nobody can plan around. State law compounds it further, since hemp cannabinoid legality already varies enormously from state to state independent of whatever Congress decides.

Even if Congress finds a way to delay or soften the federal hemp ban, that won't automatically make this benefit available everywhere. A number of states already restrict or ban hemp-derived THC and certain CBD formulations regardless of federal policy, and those state rules don't bend just because CMS created a reimbursement pathway. A Medicare beneficiary in a state with its own hemp restrictions could remain locked out of this program no matter what happens in Washington.

If you're trying to figure out whether this applies to you or someone you're caring for, the honest answer right now is that it's premature to count on it. Confirm your state's current hemp and cannabinoid laws before assuming eligibility, and keep an eye on how Congress resolves the ban before expecting any ACO near you to actually start distributing product. A program built on an 11-day runway and now stalled behind a looming prohibition has given everyone involved -- patients, providers, and suppliers -- good reason to wait and see rather than build around it.